benefits of glp-1 receptor agonists in Heart Failure Management In patients with #obesity, incretin-based

Best for: BMI 30-40, failed medical/behavioral management, not ready or higher-risk for surgery, seeking middle ground between medications and surgery

Kulcsar K, Coleman C, Beck S, Frieman M

Both, SGLT2 inhibitors and GLP1 receptor agonists, had similar effect on MACE reduction, but SGLT2 inhibitors have far more benefits in patients with heart failure

Do not take an extra dose if you miss one

Robert Kushner Mike Haney: So getting back to that we talked about obesity as a disease, and it's a disease in some part because our bodies were not evolved to live in such a food-rich, calorie-rich environment

Clinical Endocrinology & Metabolism 21, no